Vigil Neuroscience (VIGL) has made great progress in being able to advance its pipeline. It just reported interim results from its phase 2 IGNITE study, which used its drug iluzanebart [formerly ...
As healthcare becomes more entrenched in the digital revolution, the need for an approved set of protocols for care delivery — clinical pathways — is becoming increasingly critical. Clinical pathways, ...
CHICAGO--(BUSINESS WIRE)--Syntellis Performance Solutions, the leading provider of enterprise performance management software, data and intelligence solutions, today announced the launch of Focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results